Skip to main content

Table 7 Presence of allele *0201 at locus HLA-A by clinical activity status: all response-evaluable patients.

From: A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Clinical Activity Status n (%)
  Allele Absent Allele Present Allele Status Unknown Total
Benefit 4 (33.3) 8 (66.7) 0 (0.0) 12 (16.9)
CR or PR 3 (37.5) 5 (62.5) 0 (0.0) 8 (11.3)
Prolonged SD 1 (25.0) 3 (75.0) 0 (0.0) 4 (5.6)
Non-benefit 21 (45.7) 25 (54.3) 3 (6.1) 49 (69.0)
Unknown 6 (66.7) 3 (33.3) 1 (10.0) 10 (14.1)
Total 31 (46.3) 36 (53.7) 4 (5.6) 71 (100.0)
  1. Denominator for percents in columns "Allele Absent" and "Allele Present" is number of patients in row who have a known allele status.
  2. Denominator for percents in column "Allele Status Unknown" is total number of patients in row.
  3. Denominator for percents in column "Total" is number of response-evaluable patients.